BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10731123)

  • 1. Use of aromatase inhibitors in precocious puberty.
    Feuillan P; Merke D; Leschek EW; Cutler GB
    Endocr Relat Cancer; 1999 Jun; 6(2):303-6. PubMed ID: 10731123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone.
    Feuillan PP; Foster CM; Pescovitz OH; Hench KD; Shawker T; Dwyer A; Malley JD; Barnes K; Loriaux DL; Cutler GB
    N Engl J Med; 1986 Oct; 315(18):1115-9. PubMed ID: 3093862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome.
    Feuillan PP; Jones J; Cutler GB
    J Clin Endocrinol Metab; 1993 Sep; 77(3):647-51. PubMed ID: 8370686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinizing hormone-releasing hormone (LHRH)-independent precocious puberty unresponsive to LHRH agonist therapy in two girls lacking features of the McCune-Albright syndrome.
    Feuillan PP; Jones J; Oerter KE; Manasco PK; Cutler GB
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1370-3. PubMed ID: 1955519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of familial male precocious puberty with spironolactone and testolactone.
    Laue L; Kenigsberg D; Pescovitz OH; Hench KD; Barnes KM; Loriaux DL; Cutler GB
    N Engl J Med; 1989 Feb; 320(8):496-502. PubMed ID: 2492636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase inhibitors in precocious puberty: rationale and experience to date.
    Eugster EA
    Treat Endocrinol; 2004; 3(3):141-51. PubMed ID: 16026110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome.
    Nunez SB; Calis K; Cutler GB; Jones J; Feuillan PP
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5730-3. PubMed ID: 14671160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin.
    Laue L; Jones J; Barnes KM; Cutler GB
    J Clin Endocrinol Metab; 1993 Jan; 76(1):151-5. PubMed ID: 8421081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testolactone treatment of precocious puberty in McCune-Albright syndrome.
    Foster CM; Pescovitz OH; Comite F; Feuillan P; Shawker T; Loriaux DL; Cutler GB
    Acta Endocrinol (Copenh); 1985 Jun; 109(2):254-7. PubMed ID: 3925675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome.
    Roth C; Freiberg C; Zappel H; Albers N
    J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():945-8. PubMed ID: 12199354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study.
    Feuillan P; Calis K; Hill S; Shawker T; Robey PG; Collins MT
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2100-6. PubMed ID: 17405850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome.
    Eugster EA; Shankar R; Feezle LK; Pescovitz OH
    J Pediatr Endocrinol Metab; 1999; 12(5):681-6. PubMed ID: 10703542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty.
    Leschek EW; Flor AC; Bryant JC; Jones JV; Barnes KM; Cutler GB
    J Pediatr; 2017 Nov; 190():229-235. PubMed ID: 29144249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset.
    Leschek EW; Jones J; Barnes KM; Hill SC; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):175-8. PubMed ID: 9920079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia.
    Merke DP; Keil MF; Jones JV; Fields J; Hill S; Cutler GB
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1114-20. PubMed ID: 10720048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.
    Laue L; Merke DP; Jones JV; Barnes KM; Hill S; Cutler GB
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3535-9. PubMed ID: 8855797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of letrozole treatment for precocious puberty in girls with McCune-Albright syndrome.
    Estrada A; Boyce AM; Brillante BA; Guthrie LC; Gafni RI; Collins MT
    Eur J Endocrinol; 2016 Nov; 175(5):477-483. PubMed ID: 27562402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen improved final height prediction in a girl with McCune-Albright syndrome: patient report and literature review.
    Sawathiparnich P; Osuwanaratana P; Santiprabhob J; Likitmaskul S
    J Pediatr Endocrinol Metab; 2006 Jan; 19(1):81-6. PubMed ID: 16509532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management of precocious puberty in atypical presentations of McCune-Albright syndrome: a case series review.
    Bercaw-Pratt JL; Moorjani TP; Santos XM; Karaviti L; Dietrich JE
    J Pediatr Adolesc Gynecol; 2012 Feb; 25(1):e9-e13. PubMed ID: 22051789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome.
    Mieszczak J; Lowe ES; Plourde P; Eugster EA
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2751-4. PubMed ID: 18397987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.